

## Medicare Program

### List of Orphan Drugs with Increased Applicable Percentage for Calendar Quarters in 2025

The increased applicable percentage for orphan drugs, set at 26 percent for those furnished to fewer than 100 unique beneficiaries per calendar year, was finalized in the CY 2024 rulemaking and codified at [§ 414.940\(d\)\(5\)](#). To qualify, a drug must have an orphan drug designation under section 526 of the Federal Food, Drug, and Cosmetic Act and must also be approved by the FDA exclusively for indications within the designated rare disease or condition. The following table lists drugs that meet these requirements for calendar quarters in 2025.

**Table 1: List of Orphan Drugs with Increased Applicable Percentage for Calendar Quarters in 2025 (New HCPCS Code(s) in Bold)**

| HCPCS        | Healthcare Common Procedure Coding System (HCPCS) Descriptor                                       |
|--------------|----------------------------------------------------------------------------------------------------|
| J0208        | Injection, Sodium Thiosulfate (Pedmark), 100 Mg                                                    |
| J0218        | Injection, Olipudase Alfa-Rpcp, 1 Mg                                                               |
| J0221        | Injection, Alglucosidase Alfa, (Lumizyme), 10 Mg                                                   |
| J0223        | Injection, Givosiran, 0.5 Mg                                                                       |
| J0224        | Injection, Lumasiran, 0.5 Mg                                                                       |
| J0584        | Injection, Burosumab-Twza 1 Mg                                                                     |
| <b>J0850</b> | <b>Injection, Cytomegalovirus Immune Globulin Intravenous (Human), Per Vial</b>                    |
| J1203        | Injection, Cipaglucosidase Alfa-Atga, 5 Mg                                                         |
| <b>J1304</b> | <b>Injection, Tofersen, 1 Mg</b>                                                                   |
| J1305        | Injection, Evinacumab-Dgnb, 5mg                                                                    |
| <b>J1322</b> | <b>Injection, Elosulfase Alfa, 1 Mg</b>                                                            |
| J1640        | Injection, Hemin, 1 Mg                                                                             |
| J1743        | Injection, Idursulfase, 1 Mg                                                                       |
| J1746        | Injection, Ibalizumab-Uiyk, 10 Mg                                                                  |
| J1747        | Injection, Spesolimab-Sbzo, 1 Mg                                                                   |
| J1931        | Injection, Laronidase, 0.1 Mg                                                                      |
| J2277        | Injection, Motixafortide, 0.25 Mg                                                                  |
| <b>J2840</b> | <b>Injection, Sebelipase Alfa, 1 Mg</b>                                                            |
| J2860        | Injection, Siltuximab, 10 Mg                                                                       |
| J3263        | Injection, Toripalimab-Tpzi, 1 Mg                                                                  |
| J7171        | Injection, Adams13, Recombinant-Krhn, 10 Iu                                                        |
| J7205        | Injection, Factor VIII Fc Fusion Protein (Recombinant), Per Iu                                     |
| J7214        | Injection, Factor VIII/Von Willebrand Factor Complex, Recombinant (Altuviiio), Per Factor VIII I.U |
| J9032        | Injection, Belinostat, 10 Mg                                                                       |

| HCPCS        | Healthcare Common Procedure Coding System (HCPCS) Descriptor          |
|--------------|-----------------------------------------------------------------------|
| J9037        | Injection, Belantamab Mafodotin-Blmf, 0.5 Mg                          |
| <b>J9153</b> | <b>Injection, Liposomal, 1 Mg Daunorubicin And 2.27 Mg Cytarabine</b> |
| J9203        | Injection, Gemtuzumab Ozogamicin, 0.1 Mg                              |
| J9210        | Injection, Emapalumab-Lzsg, 1 Mg                                      |
| J9248        | Injection, Melphalan (Hepzato), 1 Mg                                  |
| J9269        | Injection, Tagraxofusp-Erzs, 10 Micrograms                            |
| <b>J9276</b> | <b>Injection, Zanidatamab-Hrii, 2 Mg</b>                              |
| <b>J9329</b> | <b>Injection, Tislelizumab-Jsgr, 1mg</b>                              |
| J9331        | Injection, Sirolimus Protein-Bound Particles, 1 Mg                    |
| <b>J9381</b> | <b>Injection, Teplizumab-Mzwv, 5 Mcg</b>                              |